|Bid||19.90 x 400|
|Ask||20.00 x 500|
|Day's Range||19.52 - 20.05|
|52 Week Range||12.80 - 25.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.79|
Stock Monitor: Rockwell Medical Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free research report on Impax Laboratories, Inc. (NASDAQ: IPXL ...
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see WARNINGS, Malignant Neoplasms, Endometrial Cancer].
Stock Monitor: Impax Laboratories Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Assembly Biosciences, Inc. (NASDAQ: ...
Impax Laboratories (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn. According to the plaintiffs, Impax in 2008 settled a lawsuit it filed challenging a weak patent Medicis Pharmaceutical Corp held for Solodyn by agreeing to delay releasing its generic version until 2011. In exchange, Impax received $40 million, allowing Medicis to maintain its Solodyn monopoly longer, the plaintiffs allege.
"We appreciate the strong support we have received from Impax shareholders for our transformational combination with Amneal," said Paul Bisaro, President and Chief Executive Officer of Impax. "Today's approval represents an important milestone in the process to combine our two organizations and create a diversified pharmaceutical company with stronger capabilities and greater resources.
Impax Laboratories Inc has reached a mid-trial settlement with retailers including CVS Health Corp and Rite Aid Corp who accused the drugmaker of entering into an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn. The deal, disclosed in papers filed in federal court in Boston on Sunday, resolved only part of the litigation now entering its third week of trial. Impax still faces claims by a class of consumers and insurers.
Solodyn has an indication for the treatment of inflammatory lesions of moderate to severe acne in patients 12 years and older. The generic version of Solodyn is the ninth generic tetracycline-class drug in Teva’s portfolio. According to IMS data, Solodyn Extended Release 65 mg and 115 mg tablets generated sales of ~$148 million in the United States in 2017.
BRIDGEWATER, N.J. , March 14, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The Amneal product is a therapeutic equivalent ...
Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer. The trial in Boston federal court is one of a handful to have taken place since the U.S. Supreme Court in 2013 said so-called "pay-for-delay" settlements resolving pharmaceutical patent lawsuits can violate antitrust laws. A lawyer for Impax, in his opening statement, denied there was any such arrangement to delay Solodyn's entry to the market.
Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer. Jury selection began in Boston federal court in a case centered on an alleged "pay-for-delay" settlement, in which a generic manufacturer agrees to resolve legal challenges to a brand-name drug's patents and delay making a cheaper version. The trial is one of a handful to have taken place since the U.S. Supreme Court in 2013 said that such settlements, which also involve brand-name drug companies paying the generic manufacturers, can be found to be anticompetitive.
Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn. The settlement was disclosed in papers filed in federal court in Boston on Saturday. It resolved part of the antitrust litigation Impax faces over Solodyn related to sales of the drug to direct purchasers such as retailers and wholesalers.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.
BRIDGEWATER, N.J., March 7, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL) today announced that they will jointly present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, Florida on Tuesday, March 13, 2018 at 2:35 p.m. ET. Paul Bisaro, President and CEO of Impax, Bryan Reasons, Senior Vice President and Chief Financial Officer of Impax, and Robert Stewart, President of Amneal Pharmaceuticals will participate in a fireside chat. To access a live webcast of the presentation, visit Impax's Investor Relations Web site at https://investors.impaxlabs.com/Investor-Relations.
Moody's Investors Service, ("Moody's") rated Amneal Pharmaceuticals, LLC's ("Amneal") proposed $2.7 billion senior secured term loan B1. Moody's also affirmed Amneal's current ratings ...
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.
Adamis’ Symjepi was billed as an EpiPen competitor, but the company’s search for a commercialization partner has prevented it from coming to market.
Impax Laboratories Inc (NASDAQ:IPXL), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS over the last few months. AsRead More...
The Hayward, California-based company said it had a loss of $4.18 per share. Earnings, adjusted for one-time gains and costs, came to 11 cents per share. The results did not meet Wall Street expectations. ...
BRIDGEWATER, N.J. , March 1, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched oseltamivir phosphate for oral suspension, the company's AB-rated therapeutic equivalent for Tamiflu ® , in a 6 mg/mL ...
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Impax Laboratories, Inc. (NASDAQ: IPXL ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 8:30 AM Eastern Time. ...
- Q4 2017 Total Revenues of $183 Million ; GAAP Net Loss Per Share of $4.18 ; Non-GAAP Adjusted Income Per Share of $0.11 - - Full Year 2017 Total Revenues of $776 Million ; GAAP Net Loss Per Share of ...